Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Suven Life Sciences's Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-2,761.86 Mil. Therefore, Suven Life Sciences's EV-to-EBIT ratio for today is -30.71.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Suven Life Sciences's Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-2,705.73 Mil. Therefore, Suven Life Sciences's EV-to-EBITDA ratio for today is -31.35.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Suven Life Sciences's Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹71.15 Mil. Therefore, Suven Life Sciences's EV-to-Revenue ratio for today is 1,192.27.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Suven Life Sciences (BOM:530239) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Suven Life Sciences's current Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2,761.86 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Suven Life Sciences's current Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2,705.73 Mil.
Suven Life Sciences's current Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹71.15 Mil.
Suven Life Sciences's current Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.
Suven Life Sciences's current Enterprise Value is ₹84,826.59 Mil.
Suven Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suven Life Sciences Enterprise Value Related Terms
Suven Life Sciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for Suven Life Sciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suven Life Sciences Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Suven Life Sciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Suven Life Sciences's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₹84,826.59 Mil mean?
Suven Life Sciences (BOM:530239) has a Enterprise Value of ₹84,826.59 Mil as of Aug. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Suven Life Sciences and its competitors.
Is Suven Life Sciences' Enterprise Value too high?
Suven Life Sciences' current Enterprise Value is ₹84,826.59 Mil. Overall, Suven Life Sciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' Enterprise Value compare to ZTS?
Suven Life Sciences' Enterprise Value of ₹84,826.59 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Suven Life Sciences and its competitors. Suven Life Sciences's current Enterprise Value is ₹84,826.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (BOM:530239) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹97.20, compared to a current price of ₹306.30 — trading 215.1% above its estimated fair value. The current Enterprise Value is ₹84,826.59 Mil. Suven Life Sciences' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Suven Life Sciences (BOM:530239), the current Enterprise Value is ₹84,826.59 Mil as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suven Life Sciences (BOM:530239) Overvalued in 2026?
Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued.
The current stock price of ₹306.30 is trading 215.1% above its estimated GF Value™ of ₹97.20.
GuruFocus considers Suven Life Sciences to be Significantly Overvalued.
Key valuation signals for BOM:530239:
Enterprise Value: ₹84,826.59 Mil
GF Value™: ₹97.20 vs. price of ₹306.30 (215.1% above fair value)
No single metric tells the full story. See the BOM:530239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
41GF Score
Get the complete analysis for BOM:530239
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530239 has been successfully added to your 
